A
AbolerIS Pharma
Novel monoclonal antibody inducing durable autoimmune remission
About AbolerIS Pharma
AbolerIS Pharma is a biotech company based in Nantes, France, that is currently in the pre-clinical stage. The company's primary focus is on the development of innovative immunomodulators. These are substances that help regulate the immune system, which can be crucial in treating conditions like transplant rejection, graft-versus-host-disease, and various autoimmune disorders.
Read full description
The company's target market is primarily in the healthcare sector, specifically those dealing with transplants and autoimmune diseases. This includes hospitals, clinics, and potentially pharmaceutical companies that could distribute their products once they are fully developed and approved.
AbolerIS Pharma's business model is centered around research and development. They invest in creating new, innovative immunomodulators, which they aim to patent and sell or license to healthcare providers or pharmaceutical companies. The company generates revenue through these sales or licensing deals.
Despite being a relatively young company, AbolerIS Pharma has shown significant growth and resilience over the past four years. They have successfully navigated challenges and seized new opportunities, demonstrating their potential for future success.
The company also values knowledge sharing and collaboration, as evidenced by their participation in international conferences and events. This not only helps them stay updated with the latest advancements in their field but also provides opportunities for networking and potential partnerships.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Charleroi, Belgium
- Employees
- 14
- Open positions
- None listed
- Dealroom signal
- 74.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Antibodies, Autoimmune, Spinout, Sustainable Development Goals, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, Woman Founder
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Sep 2023 | $30M | $120M | Turenne Capital · Newton BioCapital · WE Venture · Sambrinvest | ↗ |
| SEED✓Equity / VC | Nov 2020 | $2.8M | $11M | Newton BioCapital · Turenne Capital · Sham | ↗ |
Growth signals
Latest recorded traffic for AbolerIS Pharma is 880 monthly website visits, up 14.3% over the last three months. AbolerIS Pharma's team grew 7.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Turenne Capital
Newton BioCapital
Sham
Series A7 investors entered at this stage
WE Venture
Sambrinvest
SFPIM
Orsa
Criteria Venture Tech
Sound Bioventures
Wallonie Entreprendre
Other known investors4 additional known investors
Ouest Valorisation
CNRS Innovation
French National Centre for Scientific Research - CNRS
Nantes University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AbolerIS Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AbolerIS Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.